Ht-Logo-gigapixel-icon
Search
Close this search box.
Ht-Logo-gigapixel-icon
Search
Close this search box.
Sunday, November 17, 2024
Canada’s Politics and Government News Source Since 1989
Latest Paper
Sunday, November 17, 2024 | Latest Paper
Subscribe Now

TRENDING:

Jocelyn Mackie and David Brook

How a new approach to IP could have helped prevent COVID vaccine apartheid

  • A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private
Opinion | BY JOCELYN MACKIE AND DAVID BROOK | November 24, 2021
Moderna’s global rollout of its COVID vaccine would have looked very different if it had been subject to a strong and legally binding global access licence, helping to prevent the current vaccine apartheid that is inhibiting the world from getting beyond the COVID-19 pandemic, write Jocelyn Mackie and David Brook. Unsplash photograph by Ian Hutchinson

How a new approach to IP could have helped prevent COVID vaccine apartheid

Opinion | BY JOCELYN MACKIE AND DAVID BROOK | November 24, 2021
  • A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private

How a new approach to IP could have helped prevent COVID vaccine apartheid

Opinion | BY JOCELYN MACKIE AND DAVID BROOK | November 24, 2021
  • A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private
Moderna’s global rollout of its COVID vaccine would have looked very different if it had been subject to a strong and legally binding global access licence, helping to prevent the current vaccine apartheid that is inhibiting the world from getting beyond the COVID-19 pandemic, write Jocelyn Mackie and David Brook. Unsplash photograph by Ian Hutchinson

How a new approach to IP could have helped prevent COVID vaccine apartheid

  • A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private
Opinion | BY JOCELYN MACKIE AND DAVID BROOK | November 24, 2021
Moderna’s global rollout of its COVID vaccine would have looked very different if it had been subject to a strong and legally binding global access licence, helping to prevent the current vaccine apartheid that is inhibiting the world from getting beyond the COVID-19 pandemic, write Jocelyn Mackie and David Brook. Unsplash photograph by Ian Hutchinson

How a new approach to IP could have helped prevent COVID vaccine apartheid

Opinion | BY JOCELYN MACKIE AND DAVID BROOK | November 24, 2021
  • A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private

How a new approach to IP could have helped prevent COVID vaccine apartheid

Opinion | BY JOCELYN MACKIE AND DAVID BROOK | November 24, 2021
  • A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private
Moderna’s global rollout of its COVID vaccine would have looked very different if it had been subject to a strong and legally binding global access licence, helping to prevent the current vaccine apartheid that is inhibiting the world from getting beyond the COVID-19 pandemic, write Jocelyn Mackie and David Brook. Unsplash photograph by Ian Hutchinson
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Advertise

get help

Subscribe
CloseMenu